#blood-based-biomarkers

#blood-based-biomarkers

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

The funds raised through Visionaries of the Year are used for research to advance lifesaving therapies like immunotherapy, genomics and personalized medicine, which are saving lives today.

When mitochondria are exposed to tissue or blood, they lose the electrical gradient across their outer membrane. Mitochondria that lack such a gradient are recognized by a cell's internal machinery as damaged and quickly destroyed. The vast majority of previous studies involved injecting 'naked' mitochondria directly into the bloodstream or tissue sites, but the approach isn't very efficient, so researchers often have to use 'ridiculous' doses of mitochondria.

Some 1 million patients in the U.S. live with a type of heart disease called heart failure with preserved ejection fraction, or HFpEF, caused by a stiffening of a chamber of the heart that makes it much more challenging to distribute blood throughout the body. The condition has few approved therapies and high mortality rates.

More than 17,500 patients are living on the waiting list at any given time for a liver transplant. Unfortunately, there aren't enough of the available, donated organs to go around, leading to a critical and frequently deadly backlog. Roughly 10% of the patients on that waiting list die each year while waiting for the prospect of a new organ.

Scientists have long known that vast colonies of bacteria, viruses and other microorganisms—a population collectively called the microbiome—live on and inside the human body. But how they influenced our health was long a mystery. In just the past few years, we've learned that myriad factors, from the food that we consume to the amount of time that we spend sleeping to our genes to our home, all affect our microbiome.

Martschenko's argument is largely that genetic research and data have almost always been used thus far as a justification to further entrench extant social inequalities. But we know the solutions to many of the injustices in our world-trying to lift people out of poverty, for example-and we certainly don't need more genetic research to implement them. Trejo's point is largely that more information is generally better than less.

Before treatment began, participants underwent neuroimaging. Instead of relying on a single modality, the researchers fused structural connectivity (how regions are physically wired) with functional connectivity (how regions co-activate at rest). The goal was not to throw every possible feature at a black box, but to learn a constrained pattern-what the authors call structure-function "covariation"-that carries the most predictive signal for outcome. In other words, the model tries to find the smallest set of connections that meaningfully forecasts symptom change.

Public health consultant Dr Ross Keat said supporting people earlier to make small preventative changes would make "a big difference later on". Some 3,500 people in the north of the island within that age bracket are eligible for the checks. The checks will be carried out by two pre-existing nurses that support GP staff and would not replace GP appointments, Keat explained, adding that the cost would be minimal and absorbed by Ramsey Group Practice.

A virus that sickens marine mammals has been detected in Arctic waters for the first time. Scientists used drones armed with petri dishes to collect samples of blow - the air and mucus whales expel from their blowholes - from whales in northern Norway. The team identified cetacean morbillivirus in samples from humpback whales ( Megaptera novaeangliae) and one sperm whale ( Physeter macrocephalus), though the humpbacks showed no symptoms of disease.

But questions remain about the accuracy and uncertainty of these tests, and experts caution that the assays aren't ready for prime time. While the results here are encouraging, they are not yet at the level of having significant clinical benefit for individual patients, says Corey Bolton, a clinical neuropsychologist and an assistant professor of medicine at Vanderbilt University Medical Center, who was not involved in the new study.

Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.

When Lisa Dutton was declared free of breast cancer in 2017, she took a moment to celebrate with family and friends, even though she knew her cancer journey might not be over. As many as one-third of people whose breast tumours are cleared see the disease come back, sometimes decades later. Many other cancers are known to recur in the years following an initial treatment, some at much higher rates.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

Anais Muczynski, 36, an orthoptist who lives with her husband Vincent Muczynski, 41, a researcher, received her primary breast cancer diagnosis in January 2023 after discovering a quail egg-sized lump in her left breast. At the time, the London-based couple were "optimistic", as it was stage one meaning the cancer was only in the breast tissue or in the lymph nodes close to the breast and she underwent chemotherapy, immunotherapy, and a double mastectomy.